MAP2K7 and neurofibromatosis type 1: For pediatric patients with NF1 and symptomatic, inoperable plexiform neurofibromas, treatment with MEK inhibitors is recommended as the best therapeutic option to reduce tumor volume, alleviate pain, and improve quality of life and functional outcomes.